Healthcare Finance News March 24, 2025
Jeff Lagasse

The PBM says the payment model more closely aligns with the costs pharmacies often face due to “manufacturer pricing actions.”

Optum Rx has signaled a shift to a cost-based pharmacy reimbursement model that’s intended to have pharmacies pay more for brand-name drugs and less for generics.

The model will reduce variation in how pharmacies are paid.

The pharmacy benefit manager said the payment model more closely aligns with the costs pharmacies often face due to “manufacturer pricing actions.”

The change will begin immediately and full implementation will be achieved by January 2028, Optum Rx said. Affected pharmacies include more than 24,000 independent community pharmacies.

Optum Rx said the move will also make medications more affordable for consumers.

WHAT’S THE IMPACT

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Pharma, Pharma / Biotech
Makary’s FDA Has Options In Industry Fight Over Weight Loss Drugs
Faster Cancer Drug Approvals Tied to Clinical Benefits
Skepticism Hangs Over Cancer Drugs Stuck With Accelerated Approval for Years
The Future of PBMs in 2025: AI, Regulations, and Transparency Initiatives
Q&A: Pharmacy Closures, PBM Reform, and How Pharmacists Can Effectively Advocate

Share This Article